hrp0097p1-409 | Adrenals and HPA Axis | ESPE2023

Hydrocortisone (HC) versus Prednisone(P) Therapy in treating Children with Classic Congenital Adrenal Hyperplasia (CAH): Impact on statural growth weight gain and metabolic criteria

El Sayed Shayma , Soliman Ashraf , Hamed Noor , Ahmed Shayma , Alyafei Fawzia , Alaaraj Nada

Introduction: Debate still exists about the safety of long-term use of prednisone (P) versus hydrocortisone (HC) for treating children with congenital adrenal hyperplasia -21OH D (CAH).Aim: To investigate the linear growth and weigh gain as well as metabolic component in children with CAH who were treated with either HC or P since early infancy for 5 years or more.Methods: Data of ...

hrp0089p2-p102 | Diabetes & Insulin P2 | ESPE2018

A Novel Missense Variant, p.(Thr405Arg), in the SLC19A2 Gene in an Infant with Thiamine Responsive Megaloblastic Anemia Syndrome Presenting with Anemia and Diabetes but with Normal Hearing

Spehar Uroic Anita , Milenkovic Dragan , De Franco Ellisa , Rojnic Putarek Natasa , Krnic Nevena

Objectives: Thiamine responsive megaloblastic anemia syndrome (TRMA) is characterized by the clinical triad of megaloblastic anemia, non-immune diabetes mellitus and sensorineural deafness. It is a very rare autosomal recessive disease with an increased frequency in consanguineous marriages and isolated communities. The syndrome is due to intracellular thiamine deficiency which is the result of a defective high affinity low performance thiamine transporter pro...

hrp0092p2-112 | Fat, Metabolism and Obesity | ESPE2019

Identification of a Novel Heterozygous Missense Mutation in Low-density Lipoprotein Receptor Gene (LDLR) p.(Met652Thr) in an Emirati Family with Familial Hypercholesterolaemia (FH), Observed Genotype-phenotype Correlations and Pharmacotherapeutic Approaches

Al-Olabi Lara , Suliman Sara , Daggag Hinda

Background: Familial Hypercholesterolaemia (FH) is a common autosomal dominant disorder of low-density lipoprotein (LDL) metabolism characterised by elevated levels of plasma LDL-cholesterol (LDL-C), accelerated atherosclerosis and premature cardiovascular disease (CVD). In the Gulf Co-operation Council states, CVD is often diagnosed at a younger age and is the leading cause of mortality. As such, early genetic diagnosis and treatment of FH is important for ri...

hrp0089p1-p187 | Growth & Syndromes P1 | ESPE2018

A Novel Deadly Variant in the TP53 Gene Causing Li-Fraumeni Syndrome. The Importance of Clinical Awareness and the Contribution of Molecular Diagnosis in Active Prevention Within Families with Multiple Tumor Incidents at a Young Age

Bothou Christina , Spyridis Georgios P , Papantonatos Dionysios A , Stratakis Constantine A , Papadimitriou Dimitrios T

Background: Li-Fraumeni Syndrome (LFS) is an autosomal dominant hereditary cancer syndrome associated with germline pathogenic variants in in the TP53 gene and high risk of a broad range of early-onset malignancies. The 70-77% of LFS associated tumors are: breast cancer, soft-tissue sarcoma, brain tumor, osteosarcoma and adrenocortical carcinoma. However, ovarian, pancreatic and gastrointestinal track tumors are also LFS-related. The patients with LFS are at risk for a second ...

hrp0092p2-69 | Diabetes and Insulin | ESPE2019

Gluten-free Diet in Children with Recent Onset Type 1 Diabetes is Associated with Slower Pace of C-peptide Decline, Better Metabolic Control and Lower Insulin Requirement at 12 months

Neuman Vít , Pruhová Štepánka , Kulich Michal , Funda David P. , Koloušková Stanislava , Vosáhlo Jan , Romanová Martina , Petruželková Lenka , Obermannová Barbora , Cinek Ondrej , Šumník Zdenek

Objectives: Data on the role of gluten in type 1 diabetes (T1D) pathogenesis are scarce. We aimed to test whether gluten-free diet (GFD) can decelerate the decline in beta-cell capacity in newly diagnosed non-coeliac T1D children.Methods: Forty six children (aged 10.2±3.3 years) were recruited into this non-randomized self-selected intervention trial: 26 started with GFD, whereas 20 remained on standard diet. Main o...

hrp0092p3-156 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Growth Status of Children and Adolescent Born Full Term Small-for-Gestational-Age in Korea: Data from the KNHANES-V (2010–2011)

Kim Ji Hyun , Kim Dong Ho , Lim Jung Sub

Background: Currently, little information is available on current growth status according to birth weight at gestational age (BWGA) on Korean adolescents. Herein, the current height and weight of Korean adolescents who were born as small for gestational age (SGA) were compared to those of the non-SGA groups.Methods: Data from the population-based nationwide Korean survey 5th Korea National Health and Nutrition Examinatio...

hrp0086wg5.4 | ESPE Diabetes Technology and Therapeutics Working Group | ESPE2016

Use of Dual Hormone (Glucagon) v. Single Hormone (Insulin) in the Treatment of Diabetes with Close-loop System

Nimri Revital

Background: Blood glucose levels are physiologically controlled by insulin and counter-regulatory hormones, mainly glucagon. Type 1 diabetes patients are deficient in insulin and some level also glucagon. Therefore, bi-hormonal closed-loop system seems to be the best way to control glycemia.Objective and hypotheses: There are two main approaches to add glucagon: (a) as safety measures for rescue in case of hypoglycemia (2) as a mean to optimize metabolic...

hrp0097p1-101 | GH and IGFs | ESPE2023

Withdrawing growth hormone treatment at mid-puberty in idiopathic isolated growth hormone deficiency: baseline characteristics in patient-preference design study

Vliegenthart Joeri , Wit J.M. , Bakker B. , Boot A.M. , de Bruin C. , Finken M.J.J. , van der Heyden J.C. , Houdijk E.C.A.M. , van der Kamp H.J. , van Mil E.G.A.H. , Reedijk A.M.J. , Sas T.C.J. , Schott D.A. , van Setten P. , Straetemans S. , van Tellingen V. , Touwslager R.N.H. , van Trotsenburg A.S.P , Voorhoeve P.G. , van der Kaay D.C.M.

Background: The majority of children diagnosed with idiopathic isolated growth hormone deficiency (IIGHD) show a normal growth hormone (GH) secretion (assessed by GH stimulation tests) when retested at near adult height (NAH). It appears plausible that if normal stimulated GH secretion is observed in mid-puberty, continuing recombinant human GH (rhGH) treatment may only have a minor effect on NAH. The effect on NAH has never been investigated in a prospective ...

hrp0094p2-317 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Noonan syndrome patients with short stature at a single pediatric endocrinology centre

Deyanova Y. , Iotova V. , Tsochev K. , Stoyanova M. , Stoicheva R. , Mladenov V. , Bazdarska Y. , Galcheva S. , Zenker M. ,

Introduction: Noonan syndrome (NS) is caused by mutations in RAS/MAPK signaling pathway genes. About 70% of the NS patients have short stature, and human recombinant growth hormone (rhGH) is an established yet not fully standardized treatment.Objective: To assess the first 2 years rhGH treatment effectiveness in NS patients at a single centre.Materials and methods: A total of 20 (16 male) NS patien...

hrp0084p2-457 | Growth | ESPE2015

Low Plasma Ghrelin Levels in Children with Severe Protein Energy Malnutrition

Harikrishnan V , Kumar Rakesh , Sachdeva Naresh , Dayal Devi

Background: Protein energy malnutrition (PEM) is a catabolic state with altered energy balance and anorexia. Ghrelin is a peptide hormone, produced by neuro-endocrine cells in the stomach, which stimulates appetite, increases food intake and growth hormone release. Although many trials have shown short term efficacy of ghrelin to increase appetite in anorexic and cachectic patients, data on the children with PEM is scarce.Objective and hypotheses: The st...